Clinical Trial

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Name: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies — clinical trial record (NCT06914037)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: COURAGE

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Trial Details

NCT Number	NCT06914037
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital Collaborators: Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Conditions	Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
Enrollment	24 participants
Start Date	2025-03-31
Primary Completion	2028-03-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-06